Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
- PMID: 28297624
- DOI: 10.1200/JCO.2016.71.2208
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Abstract
In recent years, our understanding of the molecular pathogenesis of myeloid neoplasms, including acute myeloid leukemia (AML), has been greatly advanced by genomics discovery studies that use novel high-throughput sequencing techniques. AML, similar to most other cancers, is characterized by multiple somatically acquired mutations that affect genes of different functional categories, a complex clonal architecture, and disease evolution over time. Patterns of mutations seem to follow specific and temporally ordered trajectories. Mutations in genes encoding epigenetic modifiers, such as DNMT3A, ASXL1, TET2, IDH1, and IDH2, are commonly acquired early and are present in the founding clone. The same genes are frequently found to be mutated in elderly individuals along with clonal expansion of hematopoiesis that confers an increased risk for the development of hematologic cancers. Furthermore, such mutations may persist after therapy, lead to clonal expansion during hematologic remission, and eventually lead to relapsed disease. In contrast, mutations involving NPM1 or signaling molecules (eg, FLT3, RAS) typically are secondary events that occur later during leukemogenesis. Genetic data are now being used to inform disease classification, risk stratification, and clinical care of patients. Two new provisional entities, AML with mutated RUNX1 and AML with BCR- ABL1, have been included in the current update of the WHO classification of myeloid neoplasms and AML, and mutations in three genes- RUNX1, ASXL1, and TP53-have been added in the risk stratification of the 2017 European LeukemiaNet recommendations for AML. Integrated evaluation of baseline genetics and assessment of minimal residual disease are expected to further improve risk stratification and selection of postremission therapy. Finally, the identification of disease alleles will guide the development and use of novel molecularly targeted therapies.
Similar articles
-
Acute myeloid leukaemia genomics.Br J Haematol. 2017 Nov;179(4):530-542. doi: 10.1111/bjh.14823. Epub 2017 Jun 27. Br J Haematol. 2017. PMID: 28653397 Review.
-
Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.Genes Chromosomes Cancer. 2021 Jun;60(6):426-433. doi: 10.1002/gcc.22936. Epub 2021 Jan 22. Genes Chromosomes Cancer. 2021. PMID: 33433047
-
Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.Leuk Res. 2017 May;56:7-12. doi: 10.1016/j.leukres.2017.01.027. Epub 2017 Jan 23. Leuk Res. 2017. PMID: 28152414
-
Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.Br J Haematol. 2016 Nov;175(3):476-489. doi: 10.1111/bjh.14247. Epub 2016 Jul 29. Br J Haematol. 2016. PMID: 27470916
-
Clinical implications of novel mutations in epigenetic modifiers in AML.Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33. doi: 10.1016/j.hoc.2011.09.013. Epub 2011 Oct 29. Hematol Oncol Clin North Am. 2011. PMID: 22093580 Review.
Cited by
-
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.J Biomed Sci. 2020 Jul 21;27(1):81. doi: 10.1186/s12929-020-00674-7. J Biomed Sci. 2020. PMID: 32690020 Free PMC article. Review.
-
Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.Int J Mol Sci. 2020 Jul 20;21(14):5114. doi: 10.3390/ijms21145114. Int J Mol Sci. 2020. PMID: 32698349 Free PMC article. Review.
-
Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia.Heliyon. 2022 Sep 16;8(9):e10610. doi: 10.1016/j.heliyon.2022.e10610. eCollection 2022 Sep. Heliyon. 2022. PMID: 36164519 Free PMC article.
-
Therapeutic Applications of Human and Bovine Colostrum in the Treatment of Gastrointestinal Diseases and Distinctive Cancer Types: The Current Evidence.Front Pharmacol. 2020 Sep 11;11:01100. doi: 10.3389/fphar.2020.01100. eCollection 2020. Front Pharmacol. 2020. PMID: 33071773 Free PMC article. Review.
-
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.Cancers (Basel). 2021 Apr 26;13(9):2095. doi: 10.3390/cancers13092095. Cancers (Basel). 2021. PMID: 33926021 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous